Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled OligoG crossover study in cystic fibrosis with chronic Burkholderia colonization
2014-002125-35Phase 2Completed
- Sponsor
- AlgiPharma
- Start
- Jul 2014
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OligoG in cystic fibrosis (CF) (2 arms), sponsored by AlgiPharma. Primary endpoint: Change in Burkholderia spp. density in expectorated sputum. Started Jul 2014; status: completed.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-002125-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002125-35.